Literature DB >> 33359681

Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular Degeneration.

Tiarnan D L Keenan1, Usha Chakravarthy2, Anat Loewenstein3, Emily Y Chew4, Ursula Schmidt-Erfurth5.   

Abstract

PURPOSE: To evaluate retinal fluid volume data extracted from optical coherence tomography (OCT) scans by artificial intelligence algorithms in the treatment of neovascular age-related macular degeneration (NV-AMD).
DESIGN: Perspective.
METHODS: A review was performed of retinal image repository datasets from diverse clinical settings. SETTINGS: Clinical trial (HARBOR) and trial follow-on (Age-Related Eye Disease Study 2 10-year Follow-On); real-world (Belfast and Tel-Aviv tertiary centers). PATIENTS: 24,362 scans of 1,095 eyes (HARBOR); 4,673 of 880 (Belfast); 1,470 of 132 (Tel-Aviv); 511 of 511 (Age-Related Eye Disease Study 2 10-year Follow-On). ObservationProcedures: Vienna Fluid Monitor or Notal OCT Analyzer applied to macular cube scans. OutcomeMeasures: Intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED) volumes.
RESULTS: The fluid volumes measured in neovascular AMD were expressed efficiently in nanoliters. Large ranges that differed by population were observed at the treatment-naïve stage: 0-3,435 nL (IRF), 0-5,018 nL (SRF), and 0-10,022 nL (PED). Mean volumes decreased rapidly and consistently with anti-vascular endothelial growth factor therapy. During maintenance therapy, mean IRF volumes were highest in Tel-Aviv (100 nL), lower in Belfast and HARBOR-Pro Re Nata, and lowest in HARBOR-monthly (21 nL). Mean SRF volumes were low in all: 30 nL (HARBOR-monthly) and 48-49 nL (others).
CONCLUSIONS: Quantitative measures of IRF, SRF, and PED are important biomarkers in NV-AMD. Accurate volumes can be extracted efficiently from OCT scans by artificial intelligence algorithms to guide the treatment of exudative macular diseases. Automated fluid monitoring identifies fluid characteristics in different NV-AMD populations at baseline and during follow-up. For consistency between studies, we propose the nanoliter as a convenient unit. We explore the advantages of using these quantitative metrics in clinical practice and research. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33359681      PMCID: PMC8058226          DOI: 10.1016/j.ajo.2020.12.012

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  53 in total

1.  Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Authors:  Robyn H Guymer; Caroline M Markey; Ian L McAllister; Mark C Gillies; Alex P Hunyor; Jennifer J Arnold
Journal:  Ophthalmology       Date:  2018-11-29       Impact factor: 12.079

2.  Functional characterization and multimodal imaging of treatment-naive "quiescent" choroidal neovascularization.

Authors:  Giuseppe Querques; Mayer Srour; Nathalie Massamba; Anouk Georges; Naima Ben Moussa; Omer Rafaeli; Eric H Souied
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-21       Impact factor: 4.799

3.  Kernel regression based segmentation of optical coherence tomography images with diabetic macular edema.

Authors:  Stephanie J Chiu; Michael J Allingham; Priyatham S Mettu; Scott W Cousins; Joseph A Izatt; Sina Farsiu
Journal:  Biomed Opt Express       Date:  2015-03-09       Impact factor: 3.732

4.  Deep-learning based, automated segmentation of macular edema in optical coherence tomography.

Authors:  Cecilia S Lee; Ariel J Tyring; Nicolaas P Deruyter; Yue Wu; Ariel Rokem; Aaron Y Lee
Journal:  Biomed Opt Express       Date:  2017-06-23       Impact factor: 3.732

5.  Role of Deep Learning-Quantified Hyperreflective Foci for the Prediction of Geographic Atrophy Progression.

Authors:  Ursula Schmidt-Erfurth; Hrvoje Bogunovic; Christoph Grechenig; Patricia Bui; Maria Fabianska; Sebastian Waldstein; Gregor S Reiter
Journal:  Am J Ophthalmol       Date:  2020-04-08       Impact factor: 5.258

6.  Automated Segmentation of Lesions Including Subretinal Hyperreflective Material in Neovascular Age-related Macular Degeneration.

Authors:  Hyungwoo Lee; Kyung Eun Kang; Hyewon Chung; Hyung Chan Kim
Journal:  Am J Ophthalmol       Date:  2018-04-12       Impact factor: 5.258

7.  Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Sumit Sharma; Cynthia A Toth; Ebenezer Daniel; Juan E Grunwald; Maureen G Maguire; Gui-Shuang Ying; Jiayan Huang; Daniel F Martin; Glenn J Jaffe
Journal:  Ophthalmology       Date:  2016-01-09       Impact factor: 12.079

8.  Topical nepafenec in eyes with noncentral diabetic macular edema.

Authors:  Scott M Friedman; Talat H Almukhtar; Carl W Baker; Adam R Glassman; Michael J Elman; Neil M Bressler; Manvi P Maker; Lee M Jampol; Michele Melia
Journal:  Retina       Date:  2015-05       Impact factor: 4.256

9.  The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).

Authors:  Emily Y Chew; Traci Clemons; John Paul SanGiovanni; Ronald Danis; Amitha Domalpally; Wendy McBee; Robert Sperduto; Frederick L Ferris
Journal:  Ophthalmology       Date:  2012-07-26       Impact factor: 12.079

10.  Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial.

Authors:  Neil M Bressler; Isoken Odia; Maureen Maguire; Adam R Glassman; Lee M Jampol; Mathew W MacCumber; Chirag Shah; Daniel Rosberger; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2019-09-01       Impact factor: 7.389

View more
  8 in total

1.  Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)-a phase III, prospective, multicentre, randomized study: design and methods.

Authors:  Leonard M Coulibaly; Stefan Sacu; Philipp Fuchs; Hrvoje Bogunovic; Georg Faustmann; Christian Unterrainer; Gregor S Reiter; Ursula Schmidt-Erfurth
Journal:  Eye (Lond)       Date:  2022-07-05       Impact factor: 4.456

2.  Artificial intelligence-based strategies to identify patient populations and advance analysis in age-related macular degeneration clinical trials.

Authors:  Antonio Yaghy; Aaron Y Lee; Pearse A Keane; Tiarnan D L Keenan; Luisa S M Mendonca; Cecilia S Lee; Anne Marie Cairns; Joseph Carroll; Hao Chen; Julie Clark; Catherine A Cukras; Luis de Sisternes; Amitha Domalpally; Mary K Durbin; Kerry E Goetz; Felix Grassmann; Jonathan L Haines; Naoto Honda; Zhihong Jewel Hu; Christopher Mody; Luz D Orozco; Cynthia Owsley; Stephen Poor; Charles Reisman; Ramiro Ribeiro; Srinivas R Sadda; Sobha Sivaprasad; Giovanni Staurenghi; Daniel Sw Ting; Santa J Tumminia; Luca Zalunardo; Nadia K Waheed
Journal:  Exp Eye Res       Date:  2022-05-04       Impact factor: 3.770

3.  Evaluation of a self-imaging SD-OCT system designed for remote home monitoring.

Authors:  Judy E Kim; Oren Tomkins-Netzer; Michael J Elman; David R Lally; Michaella Goldstein; Dafna Goldenberg; Shiri Shulman; Gidi Benyamini; Anat Loewenstein
Journal:  BMC Ophthalmol       Date:  2022-06-10       Impact factor: 2.086

4.  Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV.

Authors:  Chinmayi Himanshuroy Vyas; Chui Ming Gemmy Cheung; Janice Marie N Jordan-Yu; Hitoshi Shimizu; Anna Cheng Sim Tan; Shaun Sebastian Sim; Beau James Fenner; Masahiro Akiba; Usha Chakravarthy; Kelvin Yi Chong Teo
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

Review 5.  Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy.

Authors:  Gregor S Reiter; Ursula Schmidt-Erfurth
Journal:  Ther Adv Ophthalmol       Date:  2022-03-23

6.  Prospective, Longitudinal Pilot Study: Daily Self-Imaging with Patient-Operated Home OCT in Neovascular Age-Related Macular Degeneration.

Authors:  Tiarnan D L Keenan; Michaella Goldstein; Dafna Goldenberg; Dinah Zur; Shiri Shulman; Anat Loewenstein
Journal:  Ophthalmol Sci       Date:  2021-06-26

7.  Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration.

Authors:  Maximilian Pfau; Soumya Sahu; Rawan Allozi Rupnow; Kathleen Romond; Desiree Millet; Frank G Holz; Steffen Schmitz-Valckenberg; Monika Fleckenstein; Jennifer I Lim; Luis de Sisternes; Theodore Leng; Daniel L Rubin; Joelle A Hallak
Journal:  Transl Vis Sci Technol       Date:  2021-06-01       Impact factor: 3.283

Review 8.  Evolving treatment paradigms for PCV.

Authors:  Beau J Fenner; Chui Ming Gemmy Cheung; Shaun S Sim; Won Ki Lee; Giovanni Staurenghi; Timothy Y Y Lai; Paisan Ruamviboonsuk; Gregg Kokame; Yasuo Yanagi; Kelvin Y C Teo
Journal:  Eye (Lond)       Date:  2021-07-14       Impact factor: 3.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.